Total trials
78
Active
3
Phase 3
9
Total enrollment
28,310
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Temozolomide | — | — | — | — | — | 1 |
Next readouts
- 2025-11
Top conditions
- Sepsis7
- Bronchial Asthma4
- Heart Failure4
- Pulmonary Healthy Controls3
- Breast Cancer3
- Coronary Artery Disease3
- Tumors3
- Interstitial Lung Disease3
Frequently asked questions about Universitätsmedizin Mannheim
- How many clinical trials does Universitätsmedizin Mannheim have on ClinicalTrials.gov?
- Universitätsmedizin Mannheim is listed as the lead sponsor on 78 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universitätsmedizin Mannheim's trials are in Phase 3?
- 9 of Universitätsmedizin Mannheim's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Universitätsmedizin Mannheim focus on?
- Universitätsmedizin Mannheim's most-studied conditions on ClinicalTrials.gov are Sepsis, Bronchial Asthma, Heart Failure, Pulmonary Healthy Controls, Breast Cancer.
- When are Universitätsmedizin Mannheim's next clinical trial readouts?
- Universitätsmedizin Mannheim has 1 upcoming primary-completion readout tracked here; the soonest is “Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme”, expected around 2025-11.